



the global voice of
the legal profession[®]



Follow us
@IBAEvents
#IBALifeSci

INTERNATIONAL BAR ASSOCIATION CONFERENCE 2026

A conference co-presented by the IBA Healthcare and Life Sciences Law Committee,
the IBA Intellectual Property and Entertainment Law Committee and
the IBA Technology Law Committee

12th Annual IBA World Life Sciences Conference

3–5 June 2026, Pestana Palace Lisboa, Lisbon, Portugal

Working programme

Headline
conference
sponsor



All speaker materials and biographies can be found at www.ibanet.org/conference-details/conf2781

Conference Co-Chairs

Özge Atilgan Karakulak *Gün + Partners, Istanbul; Member, IBA Intellectual Property and Entertainment Law Committee Advisory Board*

Yuval Horn *Gornitzky, Tel Aviv; Member, IBA Technology Law Committee Advisory Board*

Alejandro Luna Fandiño *Olivares, Mexico City*

Cécile Théard-Jallu *De Gaulle Fleurance, Paris; Member, IBA Healthcare and Life Sciences Law Committee Advisory Board*

Host Committee Co-Chairs

Francisco Brito e Abreu *Uría Menéndez, Lisbon*

Manuel Duraes Rocha *Abreu Advogados, Lisbon; Chair, Food and Supplements Subcommittee, IBA Healthcare and Life Sciences Law Committee*

Host Committee

Abreu Advogados

Cuatrecasas

GFDL Advogados

Gómez-Acebo & Pombo Abogados

Morais Leitão

Pérez-Llorca

PLMJ Advogados

SRS Legal

Uría Menéndez

VdA - Vieira de Almeida & Associados

Wednesday 3 June

1800 – 2100 **Host Committee reception**

ACOSTA

Avenida Infante D Henrique A

Lisbon

1100-284

All registered delegates are invited to attend.

The **IBA registration desk**, located near the entrance to the Host Committee reception venue, ACOSTA, will be open from **1800 – 2000**. Delegates may check in and collect their conference badges during these hours.

Thursday 4 June

All working sessions will take place in Belem (-1 floor)
All coffee/tea breaks will take place in Belem foyer (-1 floor)
Lunch will take place in Ajuda (Ground floor)

0730 – 1800 **Registration**
Belem foyer (-1 floor)

0730 – 0830 **Continental breakfast**

0830 – 0840 **Opening remarks by the Conference Co-Chairs**

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

Conference dinner sponsor

Abreu:
advogados

Conference refreshment break sponsor

GÜN + PARTNERS

Conference luncheon sponsor

ROPES & GRAY

Thursday continued

0840 – 0910 **Keynote address**
AI trends and impacts in the Portuguese and EU healthcare and life sciences ecosystem

Speaker

Rui Santos Ivo *Infarmed, Lisbon*

0910 – 0940 **Keynote address**
Governing the invisible: leadership, culture and governance in M&A and transformation

Speaker

Eduardo Magallanes *Taurus Management Consulting, Lisbon*

0940 – 1230 Hot topic roundtables

Introduction

Yuval Horn *Gornitzky & Co, Tel Aviv; Member, IBA Technology Law Committee Advisory Board*

Elysangela Rabelo *Demarest Advogados, São Paulo; Chair, Life Sciences Subcommittee, IBA Technology Law Committee*

1. Collaboration and licensing structures as financing tools

Moderators

Joana Silveira Botelho *Cuatrecasas, Lisbon*

Benjamin Gaw *Drew & Napier, Singapore; Chair, Development, Innovation and Commercial Transactions Subcommittee, IBA Healthcare and Life Sciences Law Committee*

Carolin Roßkothen *Taylor Wessing, Hamburg*

2. The new frontiers of telemedicine

Moderators

Francisca Paulouro *VdA Vieira de Almeida, Lisbon*

Oliver Stöckel *SKW Schwarz, Munich*

Ed Turtle *Cooley, London; Junior Developing Markets Officer, IBA Product Law and Advertising Committee*

3. Cross-border investment constraints affecting financings and exits (CFIUS risk, sensitive health/genomic data, and closing conditions)

Moderator

Gary Copelovitz *Lipa & Co, Tel Aviv*

4. Cooperations between and vertical integration of pharma/medtech and hospitals/clinics/pharmacies

Moderators

Monika Gattiker *DGS Rechtsanwälte Steuerexperten, Zürich; Treasurer, IBA Healthcare and Life Sciences Law Committee*

Guilherme Mendonça *Coloplast, São Paulo*

Lincoln Tsang *Ropes & Gray, London*

5. GLP 1s: are legal frameworks keeping pace with the weight loss revolution?

Moderators

Francisco Javier García Pérez *Uria Menendez, Barcelona*

Ignacio Gillmore *Carey, Santiago; Product Law and Advertising Committee Liaison Officer, IBA Healthcare and Life Sciences Law Committee*

Elysangela Rabelo *Demarest Advogados, São Paulo; Chair, Life Sciences Subcommittee, IBA Technology Law Committee*

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

0940 – 1230 Hot topic roundtables (continued)

6. Resolving international patent licensing disputes by arbitration – recurring issues and new developments

Moderators

Philipp Groz *Schellenberg Wittmer, Zürich*
Conna Weiner *Conna Weiner ADR, Boston*

7. Liability and accountability in open science research

Moderators

Eduardo Nogueira Pinto *PLMJ, Lisbon*
Adeniji Oni *Niji Oni & Co, Lagos; Senior Vice Chair, IBA Agriculture and Food Section*

8. The future of supplementary protection: are SPCs still fit for purpose?

Moderators

Eduardo Castillo *Perez Llorca, Madrid*
Alejandro Luna Fandiño *Olivares, Mexico City*

9. Advertising, labelling and influencer promotion of medicinal products

Moderators

Joanna Krakowiak *Wardynski & Partners, Warsaw*
Janine Reudt-Demont *Niederer Kraft Frey AG, Zürich; Social Media and Website Officer, IBA Healthcare and Life Sciences Law Committee*
Christopher Stovin *Incyte Biosciences International Sàrl, Morges*

10. Combination products (drug-device) regulation

Moderators

Leonor Pissarra *SRS Legal, Lisbon*
Koen T'Syen *Van Bael & Bellis, Brussels*
Edona Vila *Borden Ladner Gervais, Toronto; Secretary, IBA Product Law and Advertising Committee*

11. Causes and consequences of 'medical device and drugs lag'

Moderators

Jordi Faus *Faus & Moliner Abogados, Barcelona*
Jackie Mulryne *Morgan Lewis, London*
Ioana Ratescu *Novartis Pharma AG, Basel*

12. Legal challenges for novel foods across the globe

Moderators

Viviana Cervieri *Cervieri Monsuarez, Montevideo*
Anderson Ribeiro *Souto Correa Advogados, São Paulo; Scholarship Officer, IBA Healthcare and Life Sciences Law Committee*

13. When pharmaceutical patent enforcement leads to damages – for either side

Moderators

Sean Murray *Knobbe Martens Olson and Bear, Irvine*
Ricardo Nascimento Ferreira *Morais Leitão, Lisbon*
Tess Waldron *Powell Gilbert, London*

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

0940 – 1230 Hot topic roundtables (continued)

14. Pricing of medicines: an international perspective

Moderators

Andrea Abascal *Bofill Mir Abogados, Santiago; Conference Quality Officer, IBA Healthcare and Life Sciences Law Committee*

Tímea Halkó *Gedeon Richter, Budapest*

Markus Schott *Baer & Karrer, Zürich; Vice Chair, IBA Healthcare and Life Sciences Law Committee*

15. Ethical and legal challenges of human genome editing

Moderators

Julio Copo Terres *Arochi & Lindner, Mexico City; Latin American Regional Forum Liaison Officer, IBA Healthcare and Life Sciences Law Committee*

Gustaf Duhs *Stevens & Bolton, Guildford*

16. AI and data rights in life sciences/healthtech deals

Moderators

Catarina Mascarenhas *Abreu Advogados, Lisbon*

Matthias Nordmann *SKW Schwarz, Munich, Germany*

1230 – 1300

Keynote address

Trust currency: how healthcare regulatory coding and compliance are rewriting internationalisation

This keynote lecture will examine how trust is emerging as a defining currency in the international pharmaceutical landscape, and how healthcare regulatory coding and compliance are becoming decisive forces in the architecture of global expansion. The session will address the international pharmaceutical regulatory dimension of this transformation, highlighting how coding structures, regulatory classification, compliance systems and governance models are influencing market entry, product positioning, operational resilience and cross-border credibility. For international lawyers working in life sciences, this lecture will provide a sophisticated and commercially grounded reflection on the evolving relationship between regulation, trust and internationalisation in a sector where legal precision and strategic foresight are now inseparable.

Keynote Speaker

Diogo Sousa-Martins *ELS Group, Estoril*

1300 – 1345

Lunch

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

1345 – 1445 PANEL ONE

Beyond borders: rewriting the rules of global pharma patent litigation

Global pharmaceutical patent disputes are entering a new phase where litigation strategy is no longer confined to a single forum but shaped across parallel regimes – from Hatch-Waxman and US disclosure standards to the UPC's evolving cross-border toolkit and SPC/PTE frameworks in Europe. This panel will explore how recent cases and procedural shifts are redefining exclusivity, enforcement timing and forum selection, and what this means for coordinating multi-jurisdictional litigation and launch strategies.

Moderators

Manuel Duraes Rocha *Abreu Advogados, Lisbon; Chair, Food and Supplements Subcommittee, IBA Healthcare and Life Sciences Committee*

Christophe Ronse *Altius, Brussels; Corporate Counsel Forum Liaison Officer, IBA Intellectual Property and Entertainment Law Committee*

Panellists

Stella Fletcher *Bial-Portela & Ca, Porto*

Siddharth Kusumakar *Powell Gilbert, London*

Rachel Schweers *Katten Muchin Rosenman, Chicago*

1445 – 1545 PANEL TWO

Clinical trials: current trends and perspectives at a global level

This session examines how clinical trials are evolving worldwide amid technological innovation and shifting regulatory expectations. Speakers will address challenges in cross-border studies, new decentralised and e-trial models^[SF1.1], real-world evidence integration, data-driven methodologies, participant-centric trial designs, evolving ethical standards and the impact of AI. Attention will be given to international harmonisation efforts and jurisdiction-specific developments. The panel will highlight key legal and compliance implications for sponsors, investigators/involved HCPs and HCOs as a whole as well as patients and authorities. Participants will leave with a global perspective on where clinical research is headed and how to navigate its emerging risks.

Moderators

Alan Adcock *Tilleke & Gibbins, Bangkok; Co-Chair, IBA Healthcare and Life Sciences Law Committee*

Beth Weinman *Ropes & Gray, Washington; North American Regional Forum Liaison Officer, IBA Healthcare and Life Sciences Law Committee*

Panellists

Inma Garcia-Colavidas *Syneos Health, Madrid*

Raquel Redondeiro *Boehringer Ingelheim, Lisbon*

Davide Ruffo *AINDO, Trieste*

Fangzhou (Noah) Zhang *JunHe Shanghai; Regional Representative China, IBA Healthcare and Life Sciences Law Committee*

1545 – 1600 **Coffee/tea break**

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

1600 – 1700 PANEL THREE

Life sciences M&A in uncertain markets – earnouts, CVRs, contingent milestones, and IP-driven valuation mechanics/late-stage private financings and IPO alternatives (crossovers, structured preferred, PIPEs, ATMs and registered directs)

This panel will examine how volatility, regulatory complexity and shifting capital markets are reshaping transactional structures and financing strategies in the life sciences sector. Speakers will discuss the growing use of earnouts, contingent value rights, milestone based payments and IP driven valuation mechanisms as tools to bridge valuation gaps and allocate risk in M&A transactions involving biotech, pharma and healthtech companies. The discussion will also address late stage private financing alternatives to traditional IPOs, including crossovers, structured preferred equity, PIPEs, at the market offerings and registered directs, analysing their legal, governance and disclosure implications. Drawing on cross border experience, the panel will offer practical insights into structuring deals that balance investor protection, innovation incentives and long term value creation in an increasingly uncertain global market.

Moderator

Yuval Horn *Gornitzky, Tel Aviv; Member, IBA Technology Law Committee Advisory Board*

Panellists

Francisco José Brito e Abreu Uria Menendez, *Lisbon*

Colin Kavanagh *Arthur Cox, Dublin*

Oliver Kirschner *Taylor Wessing, Hamburg*

Yurika Inoue *Mori Hamada & Matsumoto, Tokyo; Asia Pacific Regional Forum Liaison Officer, IBA Healthcare and Life Sciences Law Committee*

Ariadna Padilla *Takeda, Madrid*

1700 – 1800 PANEL FOUR

Where will innovation go next? Global pharma strategies beyond the EU Pharmaceutical Package

The EU Pharmaceutical Package is more than a regional reform – it is part of a broader global shift in how innovation, access and competition are being recalibrated. This panel moves beyond an EU-centric lens to examine how different policy models are evolving in parallel: Europe's rebalancing towards access and sustainability, the continued reliance of the US on strong IP protection and market-driven incentives, and China's acceleration through investment and speed.

Against this backdrop, the discussion will focus on a central question: where will innovation go next? Panelists will explore how global pharmaceutical companies may need to adapt their IP, litigation and investment strategies in response to diverging regulatory and competitive dynamics across key jurisdictions.

Moderators

Özge Atilgan Karakulak *Gün + Partners, Istanbul; Member, IBA Intellectual Property and Entertainment Law Committee Advisory Board*

Hanna Tilus *Cirio, Stockholm; Chair, Copyright and Entertainment Law Subcommittee, IBA Intellectual Property and Entertainment Law Committee*

Panellists

Amalia Athanasiadou *Life Sciences & Antitrust, Zürich*

Maria Cedó *Esteve Healthcare, Barcelona*

Corey Salsberg *Novartis, Washington DC*

Emmanuel Saurat *Alexion Pharmaceuticals, Baar*

2030 – 2300

Conference dinner

SUD Lisboa

Avenida Brasília

Pavilhão Poente (ao lado do MAAT)

Lisbon, 1300-598

Ticket price: €140. This is a ticketed event and open to delegates and guests who have purchased tickets in advance.

*Return coaches will be provided between the conference venue (Pestana Palace Lisboa) and the conference dinner venue.

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

All working sessions will take place in Belem (-1 floor)
All coffee/tea breaks will take place in Belem foyer (-1 floor)
Lunch will take place in Ajuda (Ground floor)

0800 – 1200 **Registration**

Belem foyer (-1 floor)

0800 – 0900 **Continental breakfast**

0900 – 0910 **Greetings and opening remarks from the Committees Co-Chairs**

0910 – 0930 **Roundtable discussion and summaries**

Moderator

Yuval Horn *Gornitzky, Tel Aviv; Member, IBA Technology Law Committee Advisory Board*

0930 – 1030 **PANEL FIVE**

What are the most challenging contractual issues when discussing licensing and other agreements with strategic partners?

When technology and intellectual property rights are core assets, licensing to and from commercial partners is an essential part of a company's strategy. Licensing generates revenue, in addition to enhancing a company's value. For start-ups, leveraging on in-house R&D capabilities of large corporations, licensing in and out to strategic partners may secure their business development and increase the probability for new product launches. Figuring out the right steps to take is challenging and requires a dedicated strategy. Join us live in-house and counselling legal experts in both intellectual property and commercial matters, with long-term experience in the field of life sciences, as they discuss issues relating to licensing and share with participants their knowledge and insight.

Moderators

Gustavo Alcocer *Olivares, Mexico City*

Lorenza Ferrari-Hofer *Schellenberg Wittmer, Zürich; Intellectual Property and Media Law Committee Liaison Officer, IBA Healthcare and Life Sciences Law Committee*

Panellists

Gesilaine Bernardi *Astellas Pharma, São Paulo*

Vanessa Burrows *Simpson Thacher & Bartlett, Washington DC; Vice Chair, IBA Life Sciences Subcommittee*

Camila Marchant *Astrazeneca, São Paulo*

Maren Müller *Grünenthal Pharma, Aachen*

1030 – 1100 **Coffee/tea break**

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

1100 – 1200 PANEL SIX

Preventive health and longevity: legal perspectives shaping the future of care

As healthcare systems increasingly shift from treatment to prevention, legal frameworks play a critical role in enabling innovation in preventive health and longevity. This panel will examine how regulation, policy and compliance shape the development and adoption of preventive healthcare models, including early diagnostics, digital health and longevity-focused interventions. Speakers will explore the legal and ethical challenges surrounding personalised medicine, data use, clinical validation and cross-border care in life sciences. The discussion will also address ethical considerations such as fair access to healthcare and patient protection in rapidly evolving preventive and longevity markets. By bringing together legal and healthcare perspectives, the panel will highlight how law can act as a catalyst for sustainable, preventive and longer-life-focused health systems.

Moderators

Elisa Stefanini *Portolano Cavallo, Rome; Chair, Digital Healthcare and Regulation Subcommittee, IBA Healthcare and Life Sciences Law Committee*

Cecile Theard-Jallu *De Gaulle Fleurance, Paris; Member, IBA Healthcare and Life Sciences Law Committee Advisory Board*

Panellists

Raul Azevedo *Chief Operating Officer, European Longevity Hub, Lisbon*

Efstathia Gkika *Baxter, Zürich*

Carla Sousa Pontes *CUF Hospitals, Lisbon*

Thomas Szucs *University of Basel, Basel*

1200 – 1210 **The 2026 IBA Healthcare and Life Sciences Law Committee annual survey: trade and distribution of therapeutic products (pharmaceuticals/biologics and medical devices)**

Presented by

Beth P Weinman *Ropes & Gray, Washington DC; North American Regional Forum Liaison Officer, IBA Healthcare and Life Sciences Law Committee*

Markus Schott *Bär & Karrer, Zurich; Vice-Chair, IBA Healthcare and Life Sciences Law Committee*

1210 – 1220 **Closing remarks**

1220 – 1400 **Lunch**

1630 **Old Lisbon Tour**

A two-hour optional guided tour of Lisbon's historic districts organised by the Host Committee.

Old Lisbon Tour itinerary

Baixa – Rua Augusta Arch – Cathedral (Sé) – Largo Portas do Sol – Santa Luzia Viewpoint – Graça – Senhora do Monte – São Vicente de Fora Monastery – Campo de Santa Clara – Feira da Ladra – National Pantheon – Fado Museum – Alfama – Comércio Square. The tour includes a stop for a Ginginha, a famous portuguese liqueur.

The tour is open only to those who have booked in advance. Participants who have booked should already have received the pick-up location, together with the name and contact details of their assigned guide/driver, from the tour company.

MOBILE TELEPHONES

Delegates are requested to ensure that mobile telephones and any other portable devices are switched to silent in working sessions.

Welcome to Lisbon!

**Hovione is proud to sponsor
the 12th Annual IBA World
Life Sciences Conference**

We are a specialized, global CDMO offering integrated services across Drug Substances, Drug Product Intermediates, and Drug Products that accelerate the delivery of innovative medicines to patients.

Trusted by 19 of the top 20 global pharmaceutical companies, Hovione has a hand in medicines treating more than 80 million patients each year. This impact is what drives us - it's why we are In it for Life.



**Learn more about how we connect science,
technology and people to improve lives**

Abreu:
advogados

Unlocking legal innovation

Knowledge-based work defines our culture as we seek collaborative solutions.

Setting the standard in expertise that ignites Portugal and Lusophone Africa's boldest business models.

We are the future in progress.

Thinking about tomorrow?
Let's talk today.

abreuadvogados.com

Lisbon | Oporto | Funchal
Angola | Brazil | Cape Verde | China | Mozambique | East Timor